#### REMARKS

Claims 1-20 are pending in this application. Claim 1 is the sole independent claim. Claim 6 has been amended to recite "the counter electrode" in place of "a conductive substrate" for purposes of clarification and not to limit its scope. This amendment finsds support at page 19, lines 2-5 of the specification. Claim 9 has been amended to recite "the metal oxide semiconductor mesoporous film" in place of "a metal oxide semiconductor mesoporous film", as suggested by the Examiner, for purposes of clarification and not to limit its scope. The amendments to the claims do not introduce any new matter and do not raise any new issues. As a minimum, the amendments to the claims reduce the issues for Appeal in the event an Appeal is needed.

The objection to Claim 9 and rejection of Claim 6 under 35 USC §112, second paragraph have been overcome by the above amendments to these claims.

Claims 1-5 and 9-16 are rejected under 35 USC 103 as being obvious over WO 2004/017452 to Yoshikawa et al. in view of US Patent 5,188,768 to Sotomura. The cited references do not render unpatentable the present invention.

As is clear from the disclosure of the present application, especially from claims 1 and 5, important aspects of the present invention reside in the electrolyte comprising: (i) a layered clay mineral and/or an organically modified layered clay mineral; and (ii) an ionic liquid.

This electrolyte is useful, as an electrolyte layer, for a photovoltaic device in which the electrolyte layer is located between a photoelectrode and a counter electrode. As disclosed on page 14, lines 5 - 26 of the specification, the "ionic liquid" (e.g., quaternary ammonium salts, imidazolium salts, pyridium salts, pyrrolidinium salts, piperidinium salts) is known in the art and, as shown by the term "liquid", exists in the form of a liquid under an ambient condition (i.e., a room temperature) and, therefore, when used as an electrolyte, the use of a solvent is not necessary, unlike the other conventional electrolytes known in the art. This is completely absent in the cited references.

Yoshikawa et al relate to an electrolyte for dye-sensitized solar cells wherein an oxidation-reduction is carried out by a vulcanized rubber, a polyphosphazene, a porous body comprising a high molecular material comprising a high molecular material which has a three-dimensional continuous network skeleton structure or an EVA resin film.

According to the Office Action, Yoshikawa et al. teach an electrolyte comprising a oxidation-reduction substance containing an ionic liquid, e.g. 1,2 dimethy1-3-propylimidazolium iodide, carried by a vulcanized rubber containing clay (abstract; [0112]; [0200 - 0207]), although Yoshikawa et al do not expressly teach a layered clay mineral and/or an organically modified layered clay mineral.

However, this is not correct and differs from the present invention in the following points:

(i) 1,2-dimethy1-1,3-propyl imidazolium iodide is not an ionic liquid, because the melting point of the 1,2-dimethyl-1,3-propyl imidazolium iodide (i.e., oxidation-reduction substance) is in the form of a solid (i.e., white-light yellow, crystal-powder) at 20°C, which is not a liquid under an ambient condition (See the enclosed Reference 1, i.e., section lx on page 2 of "Material Safety Data Sheet").

Thus, Yoshikawa et al neither disclose nor teach the use of the ionic liquid.

(ii) Yoshikawa et al. neither disclose nor teach the use of the layered clay mineral (and/or the organically modified layered clay mineral, the same hereinbelow) in the ionic liquid.

Yoshikawa et al. merely disclose the use of clay (note: not the layered clay mineral) in the vulcanized rubber. As is well known in the art, the "clay" mentioned in Yoshikawa et al is used, as a filler such as carbon black, silica, calcium carbonate and the like. In addition, the vulcanized rubber is not used in the present invention.

Consequently, the use of the ionic liquid and the use of the layered clay mineral (even the clay) in an ionic liquid are completely absent in Yoshikawa et al.

Sotomura does not overcome the above discussed deficiencies of Yoshikawa et al. with respect to rendering unpatentable the present invention. Sotomura relates to a solid form electrolyte composite comprising an ion-exchanging layered compound (e.g. a clay material) and an ionic material MX (e.g., LiI, LiClO<sub>4</sub>, LiCF<sub>3</sub>SO<sub>3</sub>, ...).

This is completely different from the present invention. Especially, the use of the layered clay mineral in an ionic liquid is completely absent in Sotomura.

Claims 6-8 and 17-20 are rejected under 35 USC 103 as being obvious over WO 2004/017452 to Yoshikawa et al. in view of US Patent 5,188,768 to Sotomura and of US patent application publication 2005/0072462 to Kang et al.

Kang does not overcome the above discussed deficiencies of Yoshikawa et al. and Sotomura with respect to rendering unpatentable the present invention. Kang et al were relied upon for a disclosure of a solid state dye-sensitized solar cell in which, a counter electrode coated with polyaniline can be employed (abstract, [0024]).

However, again the use of the layered clay mineral in an ionic liquid is completely absent in Kang et al, as is the case with the other references. Consequently, the use of the layered clay mineral and/or the organically modified clay mineral in an ionic liquid in the present invention is completely absent in the cited references or any combination thereof. Accordingly, claims6-8 and 17-20 are patentable for at least those reasons as to why claim 1 is patentable.

Concerning obviousness, Graham V. John Deere, 383 U.S. 1,148 U.S.P.Q. 459 (1966) outlines the approach that must be taken when determining whether an invention is obvious. In Graham, the Court stated that a patent may not be obtained if the subject matter would have been obvious at the time the invention was made to a person having ordinary skill in the art, but emphasized that nonobviousness must be determined in the light of inquiry, not quality. Approached in this light, §103 permits, when followed realistically, a more practical test of patentability. In accordance with Graham, three inquiries must be made in determining whether an invention is obvious:

(1) The scope and content of the prior art are to be determined.

(2) The difference between the prior art and the claims at issue are to be ascertained.

- (3) The level of ordinary skill in the pertinent art resolved.
- (4) Evaluating evidence of secondary considerations, such as commercial success, long felt but unsolved needs and failure of others, etc. Also see KSR Int'l Co. v. Teleflex, Inc, 127 S. Ct. 1727 (2007).

Against this background, the obviousness or nonobviousness of the subject matter is determined. Secondary considerations, such as unexpected results, commercial success, long felt but unsolved needs, failure of others, etc., can be utilized to give light to the circumstances surrounding the origin of the subject matter sought to be patented.

In conjunction with interpreting 35 U.S.C. §103 under Graham, the initial burden is on the Patent Office to provide some suggestion of the desirability of doing what the inventor did, i.e. the Patent Office must establish a prima facie case of obviousness. To support the conclusion that the claimed invention is directed to obvious subject matter, either the references must expressly or impliedly suggest the claimed invention, or the Patent Office must present a convincing line of reasoning as to why the artisan would have found the claimed invention to have been obvious in light of the teachings of the references.

To establish a prima facia case of obviousness, three basic criteria must be met:

- 1. There must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference.
  - There must be a reasonable expectation of success.
- 3. The prior art reference (or references when combined) must teach or suggest all the claim limitations.

The mere fact that the cited art may be modified in the manner suggested in the Office Action does not make the modification obvious, unless the cited art suggest the desirability of the modification or adequate rationale exists to do so. No such suggestion appears in the cited art in

this matter nor has the requisite rationale been adequately articulated. The Examiner's attention is kindly directed to KSR Int T Co. v. Teleflex, Inc., supra; In re Lee 61 USPQ2d 1430 (Fed. Cir. 2002), In re Dembiczak et al. 50 USPQ2d. 1614 (Fed. Cir. 1999), In re Gordon, 221 USPQ 1125 (Fed. Cir. 1984), In re Laskowski, 10 USPQ2d. 1397 (Fed. Cir. 1989) and In re Fritch, 23, USPQ2d. 1780 (Fed. Cir. 1992).

Also, the cited art lacks the necessary direction or incentive to those of ordinary skill in the art to render a rejection under 35 USC 103 sustainable. The cited art fails to provide the degree of predictability of success of achieving the properties attainable by the present invention as discussed above needed to sustain a rejection under 35 USC 103. See KSR Int'l Co. v. Teleflex, Inc., supra; Diversitech Corp. v. Century Steps, Inc. 7 USPQ2d 1315 (Fed. Cir. 1988), In re Mercier, 187 USPQ 774 (CCPA 1975) and In re Naylor, 152 USPQ 106 (CCPA 1966).

Moreover, the properties of the subject matter and improvements and advantages which are inherent in the claimed subject matter and disclosed in the specification are to be considered when evaluating the question of obviousness under 35 USC 103. See KSR Int'l Co. v. Teleflex, Inc., supra; Gillette Co. v. S.C. Johnson & Son, Inc., 16 USPQ2d. 1923 (Fed. Cir. 1990), In re Antonie, 195, USPQ 6 (CCPA 1977), In re Estes, 164 USPQ 519 (CCPA 1970), and In re Papesch, 137 USPO 43 (CCPA 1963).

No property can be ignored in determining patentability and comparing the claimed invention to the cited art. Along these lines, see *In re Papesch*, supra, *In re Burt et al.* 148 USPQ 548 (CCPA 1966), *In re Ward*, 141 USPQ 227 (CCPA 1964), and *In re Cescon*, 177 USPQ 264 (CCPA 1973). In view of the above, consideration and allowance are respectfully solicited.

In view of the above, consideration and allowance are respectfully solicited.

In the event the Examiner believes another interview might serve in any way to advance the prosecution of this application, the undersigned is available at the telephone number noted below.

The Office is authorized to charge any necessary fees due with this paper to Deposit Account No. 22-0185, under Order No. 21713-00032-US1 from which the undersigned is authorized to draw.

Dated: May 12, 2011 Respectfully submitted,

Electronic signature: /Burton A. Amernick/
Burton A. Amernick
Registration No.: 24,852
CONNOLLY BOVE LODGE & HUTZ LLP
1875 Eye Street, NW
Suite 1100
Washington, DC 20006
(202) 331-7111
(202) 293-6229 (Fax)
Attorney for Assignee





# Material Safety Data Sheet

HAZARO VARNINGS: BISK PINSASESS IN PROTECTIVE CEGTURG IN A STATE OF THE CEGTURG IN THE CEGTURG I

Chemical Name	1,2-Dimethyl-3-propylimidazolium lodide		
Catalog Number	03963	Supplier	TCi America 9211 N. Harborgate St.
Synonym	1H-Imidazofium, 1,2-dimethyl-3-propyl-, iodide (1:1) (CA INDEX NAME)		Portland OR 1-800-423-8616
Chemical Formula	C <sub>8</sub> H <sub>16</sub> IN <sub>3</sub>		
CAS Number	218151-78-1	151120	CB - 1245 350 2/4506 U.S.

Section II. Composition and information on Ingredients				
Çhemicai Name	CAS Number	Percent (%)	. TLWFEL	Toxicology Data
1,2-Dimetry4-3-propylamisissolikum todisis	218151-78-1	Mr. 98.0 (HPLC,T)	Not šveliabie.	Not evalletva,

Section III.	azards Identification
Acute Health Effects	Initiating to eyes and skin on contact. Initialistion causes initiation of the lungs and respiratory system. Initiammation of the sye is characterized by licking, scaling, reddening, or, occasionally, bijetering, bracking, and itching. Skin inflammation is characterized by licking, scaling, reddening, or, occasionally, bijetering.  Follow safe industrial hygiene practices and always west proper protective equipment when handling this compound.
Chronic Health Effects	CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TONICITY: Not available. Reposted or prolonged exposure to the compound is not known to apprayate existing medical conditions.

	Section IV	First Aid Measures
	Eye Consact	Check for and remove any contact tenses. In case of contact, immediately flush eyes with planty of water for at least 15 minutes. Set medical attention.
-	Skin Contact	in case of contact, immediately flush skin with plenty of water. Remove contaminated diothing and shales. Wash diothing before reuse. Get medical attention.
	Inhalation	If the violim is not breathing, perform mouth-to-mouth resuscitation. Lossen tight clothing such as a collar, tie, best of waterband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not improve.
,	logesden	INDUCE VOMITING by sticking finger in throat. Lower the head so that the vonsit will not reenter the mouth and throat. Lossen tight clothing such as a collar, ite, but or waistband. If the victim is not breathing, perform mouth-to-mouth resuscitation. Exemine the lips and mouth to escential whether the tissues are damaged, a possible indication that the toxic material was breathed the attention of such stress bounder is not constitute.

Plannability	May be combustible at high temperature.	Auto-Ignition	Not available.
Flash Points	Not avallable.	Flammable Limits	Not evaliable.
Combustion Products	These products are toxic carbon oxides (CO,	CO <sub>2</sub> ), nimpen oxides (NO, NO	), haloganated compounds.
Fire Hazards	Not avsilable.		
Explosion Hazards	Pisks of explosion of the product in presence of mechanical impact; Not available. Risks of explosion of the product in presence of static discharge: Not available.		
Fire Fighting Media and Instructions	SMALL FIRE: Use ORY chemical provider.  LARGE FIRE: Use water spray, fog or foam.  Consult with local fire authorities before after		verstions

#### 1,2-Dimethyl-3-propylimidazolium lodide D3903 Section VI: Accidental Release Measures Spill Cleanup Initating material. Use a shovel to put the material into a convenient weste disposal container. Finish cleaning the spill by rinsing any Instructions conteminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on disposal. Section VII. Handling and Storage IRRITANT. Keep away from heat. Mechanical extraust required. When not in use, tightly seal the compliner and stone in a Handling and Storage dry, copi piace. Avoid excessive heat and light. Do not breathe dust. Information Always store away from incompatible corridounds such as cridicing agents Exposure Controls/Personal Protection Section VIII. Engineering Controls Lise process endosures, local exhaust venticulor, of other engineering controls to keep airborne levels below recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants below the exposure limit. Spleafi gaggles, Lab coat. Dust respirator. Boats. Glaves. Suggested protective dothing might not be sufficient, consult a specialist BEFORE handling this product. Se sure to use a MSHANIOSH approved respirator or equivalent. Personal Protection Not available. Exposure Limits Section IX. Physical and Chemical Properties Physical state @ 20°C Solid. (White - light yellow, crystal ~ Solubility Soluble in evaper. powder.) Not available. Specific Gravity 286.12 Molecular Weight Partition Operacient Not available Boiling Point Not available. Vapor Pressure Not applicable. Not available. Not available. Melting Point Vapor Density Not available. Volatility Not available. Refractive Index Not available. Critical Temperature Not available. Odex Not available. Viscosity Not available. Tassa Section X. Stability and Reactivity Data Stability This material is stable if stored under proper conditions. (See Section VII for Instructions) Conditions of Instability Avoid excessive heat and light. Locompatibilities Resolive with old sizing agents. Section XIII Toxicological Information Not available RTECS Number Routes of Exposure Eya Contact. Ingestion, Inhalation. Not available. Toxicity Data Chronic Toxic Effects CARCINOGERIO EFFECTS: Not available. MUTAGERIC EFFECTS : Not available TERATOGENIC EFFECTS : Not available DEVELOPMENTAL TOXICITY: Not available. Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

Section XII.	cological Information
Ecotoxicity	Not avaliable.
Environmental Pale	Not available.

intiating to eyes and skin on contact. Inhalation causes initation of the lungs and respiratory system. Inflammation of the eye is characterized by technics, watering, and fiching. Sidn inflammation is characterized by technics, scaling, reddening, or,

Follow sala industrial hygiene practices and always wear proper protective equipment when handling this compound.

Acrote Toxic Effects

occasionally, blistering

D3903	1,2-Dimethyi-3-propylimldazolium lodide Page 3
Section XIII.	isposal Considerations
Waste Disposal	Recycle to process, if possible. Consult your local regional authorities. You may be able to discoive or mix material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all laderal, state and local regulations when disposing of the substance.
Section XIV.	ransport Information
DOT Classification	Not a DOT controlled material (United States).
PIN Number	Not applicable.
Proper Shipping Name	Not applicable.
. Packing Group (PG)	Not applicable.
DOT Pictograms	
- Allena	

Section XV O	ther Regulatory Information and Pictograms
TSCA Chemical Inventory (EPA)	This product is NOT on the EPA Toxic Substances Control Act (TECA) inventory. The following notices are required by 40 CFR 720.36 (C) for those products not on the inventory list:  (i) These products are supplied solely for use in research and development by or under the supervision of a technically qualified individual as defined in 40 CFR 720.0 et sec.  (ii) The health tisks of these products have not been fully determined. Any Information that is or becomes available will be supplied on an MSDS sheet.
WHMIS Classification (Canada)	No: available.
EUVECS Number (EEC)	Not avaliable,
EEC Risk Statements	R36/37/36- Infiniting to eyes, respiratory system and skin.
Japanese Regulatory Data	Not available.

## Section XVI. Other Information

Version Li Validated on 1/8/2010. Printed 1/8/2010.

### Notice to Reader

TCI blorstory characters are for presently proposed and are NOT intended for two as deaps, food additions, bassesholds, or president. The information bursts is believed in the connect, the does are pilled to be an above a good. Neither the above areas supplied for any of its administer seasons say liability withdrawers for the accuracy or complements of the information consisted bursts. Float determination of anisolative of any notional is the acts responsibility of the uses. As chemical respects must be transled with the companion first (help chemical), introducing for the uses. As chemical respects must be transled with the companion first (help chemical) introducing for the latent of the present and the bursts of the present all transled in proper sides, becausely, because and the intended proper sides, becausely, because and the adjust of the supple sides and the proper sides, because of the transled and adjust of the side adjust to though sends the contract and the proper sides, because as the neighboring of the side of the proper to the proper sides of the side of the proper sides and the proper sides of the side of the proper sides of the side of the proper sides and the proper sides of the proper sides of the side of the proper sides of the sides of the proper sides of the proper sides of the sides of the sides of the sides of the proper sides of the proper sides of the si

Printed \$52000.